Inmune Bio (INMB) Total Current Liabilities (2018 - 2026)
Inmune Bio (INMB) posted Total Current Liabilities of $5.4 million for Q1 2026, down 35.98% sequentially from $8.4 million in Q4 2025, and down 32.03% YoY from $7.9 million in Q1 2025.
Inmune Bio (INMB) Total Current Liabilities (2018 - 2026) Analysis & Trends
Inmune Bio has reported Total Current Liabilities for 9 years, with the latest figure at $5.4 million in Q1 2026.
- Quarterly Total Current Liabilities fell 32.03% year-over-year to $5.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $5.4 million (down 32.03% YoY) and the FY2025 annual result came in at $8.4 million, up 16.55% from the prior year.
- Total Current Liabilities retreated to $5.4 million in Q1 2026 per INMB's latest filing, from $8.4 million in the prior quarter.
- Over five years, Total Current Liabilities peaked at $18.5 million in Q4 2023 and troughed at $2.3 million in Q2 2022.
- A 5-year average of $10.0 million and a median of $8.6 million in 2025 frame the typical range for Total Current Liabilities.
- The sharpest annual moves came in 2023 and 2024: Total Current Liabilities jumped 471.33% in 2023, then slumped 60.89% in 2024.
- Over 5 years, Total Current Liabilities stood at $10.9 million in 2022, then surged by 69.12% to $18.5 million in 2023, then plunged by 60.89% to $7.2 million in 2024, then gained by 16.55% to $8.4 million in 2025, then tumbled by 35.98% to $5.4 million in 2026.
- According to Business Quant data, Total Current Liabilities over the past three periods registered $5.4 million, $8.4 million, and $7.4 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.09 Bn | 131.23 Bn | 2.84 Bn | 3.94 Bn |
| 2 | Regeneron Pharmaceuticals | 85.66 Bn | 77.66 Bn | 3.93 Bn | 5.53 Bn |
| 3 | Argenx Se | 64.86 Bn | 59.67 Bn | 1.37 Bn | 1.58 Bn |
| 4 | Moderna | 58.07 Bn | 52.93 Bn | 52.00 Mn | 2.53 Bn |
| 5 | BeOne Medicines | 41.87 Bn | 36.77 Bn | 1.53 Bn | 2.12 Bn |
| 6 | Alnylam Pharmaceuticals | 31.45 Bn | 28.15 Bn | 992.69 Mn | 1.51 Bn |
| 7 | BioNTech SE | 27.90 Bn | 9.51 Bn | 668.28 Mn | 2.49 Bn |
| 8 | Insmed | 27.40 Bn | 26.24 Bn | 358.27 Mn | 438.74 Mn |
| 9 | Royalty Pharma | 27.28 Bn | 26.45 Bn | - | 630.93 Mn |
| 10 | Inmune Bio | 61.59 Mn | 43.18 Mn | - | 5.89 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 5.89 Mn |
| Mar 31, 2026 | 5.39 Mn |
| Dec 31, 2025 | 8.42 Mn |
| Sep 30, 2025 | 7.36 Mn |
| Jun 30, 2025 | 8.59 Mn |
| Mar 31, 2025 | 7.93 Mn |
| Dec 31, 2024 | 7.22 Mn |
| Sep 30, 2024 | 13.82 Mn |
| Jun 30, 2024 | 15.05 Mn |
| Mar 31, 2024 | 17.45 Mn |
| Dec 31, 2023 | 18.47 Mn |
| Sep 30, 2023 | 14.36 Mn |
| Jun 30, 2023 | 13.06 Mn |
| Mar 31, 2023 | 10.28 Mn |
| Dec 31, 2022 | 10.92 Mn |
| Sep 30, 2022 | 6.90 Mn |
| Jun 30, 2022 | 2.29 Mn |
| Mar 31, 2022 | 3.23 Mn |
| Dec 31, 2021 | 4.36 Mn |
| Sep 30, 2021 | 4.81 Mn |